Technical Briefing on Health Care Sector: Gilead Sciences, Halozyme
Therapeutics, NPS Pharma, and InterMune
LONDON, December 26, 2013
LONDON, December 26, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
On Tuesday, December 24, 2013, the U.S. equity market advanced. The S&P 500
ended the day at 1,833.32, up 0.29%; the Dow Jones Industrial Average closed
at 16,357.55, up 0.39%; and the NASDAQ Composite Index finished at 4,155.42,
up 0.16%. The S&P 500 Health Care Sector Index edged 0.08% lower to close the
session at 638.05; and the S&P 500 Biotechnology Industry Index finished at
2,784.14, down 0.38%. The S&P 500 Biotechnology Industry Index has gained
1.42% in the previous three trading sessions and 11.23% in the last three
months, outperforming the S&P 500, which has gained 1.31% and 8.30% during the
respective periods. The major movers in the Health Care Sector included Gilead
Sciences Inc. (NASDAQ: GILD), Halozyme Therapeutics Inc. (NASDAQ: HALO), NPS
Pharmaceuticals Inc. (NASDAQ: NPSP) and InterMune Inc. (NASDAQ: ITMN). All
these companies are tracked by AAAResearchReports.com. Download free technical
analysis and charting reports on GILD, HALO, NPSP, and ITMN now at:
Shares in Gilead Sciences Inc. vacillated between $74.21 and $75.03 before
closing the day at$74.96, down 0.04%. A total of 4.53 million shares were
traded on Tuesday, which is below the daily average volume of 10.26 million.
The company's shares have gained 21.43% in the previous three months and 2.08%
in the last three trading sessions, outperforming the S&P 500, which has
gained 8.30% and 1.31% during the respective periods. Furthermore, Gilead
Sciences Inc.'s stock is trading above its 50-day and 200-day moving averages
of $70.74 and $59.33, respectively. Download free research on GILD today by
Halozyme Therapeutics Inc.'s stock hit a new 52-week high of $15.71 on
Tuesday, finishing the day 1.24% higher at $15.57. The company's stock
fluctuated between $15.33 and $15.71 during the trading session. A total of
0.53 million shares were traded, which is below the daily average volume of
1.74 million. The company's shares have gained 59.69% in the previous three
months and 9.03% in the last one month, outperforming the S&P 500, which has
advanced 8.30% and 1.71% during the respective periods. Moreover, Halozyme
Therapeutics Inc.'s stock is trading above its 50-day and 200-day moving
averages of $13.15 and $8.86, respectively. Sign up and have access to our
free report on HALO at:
NPS Pharmaceuticals Inc.'s stock edged 0.27% lower on Tuesday, even the US
equity market posted gains. The company's shares closed the day at $29.59,
after vacillating between $29.15 and $29.86 during the trading session. A
total of 0.90 million shares were traded, which is below the daily average
volume 2.17 million. Despite Tuesday's decline, the company's shares have
surged 22.63% in the previous one month and 10.00% in the last three trading
sessions, outperforming the S&P 500, which has gained 1.71% and 1.31% during
the respective periods. Further, NPS Pharmaceuticals Inc.'s stock is trading
above its 50-day and 200-day moving averages of $26.35 and $20.56,
respectively. Sign up and read the complimentary report on NPSP at:
InterMune Inc.'s stock closed the day at $14.76, down 0.14% from the previous
day's closing price of $14.78. On Tuesday, the company's shares oscillated
between $14.53 and $14.90 during the trading session. A total of 0.45 million
shares were traded, which is below the daily average volume of 1.06 million.
Despite Tuesday's losses, the company's shares have gained 14.51% in the
previous one month and 9.41% in the last three trading sessions, outperforming
the S&P 500, which has gained 1.71% and 1.31% during the respective periods.
Moreover, InterMune Inc.'s stock is trading above its 50-day and 200-day
moving averages of $13.58 and $12.21, respectively. The free report on ITMN
can be downloaded by signing up now at:
1.This is not company news. We are an independent source and our views do
not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
only human and are prone to make mistakes. If you notice any errors or
omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
increase awareness for mentioned companies to our subscriber base and the
4.If you wish to have your company covered in more detail by our team, or
wish to learn more about our services, please contact us at
5.For any urgent concerns or inquiries, please contact us at
6.Are you a public company? Would you like to see similar coverage on your
company? Send us a full investors' package to
research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
SOURCE AAA Research Reports
Contact: Peter F. Jones - Phone #: +1(646)396-9126
Press spacebar to pause and continue. Press esc to stop.